Gut microbiota and immunometabolism in obesity.
Gut bacteria and their metabolic byproducts shape immune cell function in ways that either protect against or fuel obesity-related inflammation, suggesting microbiota targeting as a therapeutic angle.
This Gut Microbes review synthesizes how gut microbiota metabolites (SCFAs, bile acids, amino acids) reprogram immune cell metabolism through mTOR/AMPK pathways in obesity, driving chronic inflammation and cardiometabolic disease. It proposes modulating gut microbiota function as a strategy to restore immunometabolic homeostasis in obesity — a rapidly emerging mechanistic framework for GLP-1/SGLT2-adjacent intervention.
What the study was
- Study design
- Narrative review
- Population
- Obese patients and mouse/cell line models
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Gut Microbes
Why it surfaced
High-quality Gut Microbes review; immunometabolism framework in obesity is emerging and timely; IATA-CSIC Spain group has strong microbiome expertise; review design limits score.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.